BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-6093 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-6093\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07134998-11111@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:HRS-6093: Phase 1 readout est. (NCT07134998)
DESCRIPTION:HRS-6093\, phase 1\, Advanced Solid Tumors.\nStudy: Phase I Stu
 dy of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G
 12D Mutations\nEstimated primary completion: May 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hrs-6093#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07134998
URL:https://assetmemo.bio/drug/hrs-6093#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
